CMD011
/ Zhejiang Shimai Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 21, 2025
International endorsement, global leader | Shimai Pharmaceuticals' GPC3×CD3 bispecific antibody CMD011 obtains FDA's implied clinical trial approval [Google translation]
(bydrug.pharmcube.com)
- "On February 21, 2025, Zhejiang Shimai Pharmaceutical Co., Ltd.'s independently developed Class I therapeutic biological product CMD011 for injection received FDA implicit approval . This product is a fully human anti-GPC3×CD3 bispecific antibody intended for the treatment of advanced hepatocellular carcinoma. This is the third GPC3×CD3 bispecific antibody in the world to be approved by the FDA for clinical trials."
New trial • Hepatocellular Cancer
1 to 1
Of
1
Go to page
1